CGBio
Develops patient-specific titanium cranial and craniofacial implants using Laser Powder Bed Fusion (LPBF) and bioceramic 3D printing, enabling rapid 5-day turnaround for surgical reconstruction.
- CEO / Founder
- Yoo Hyun-seung
- Team Size
- 201-500
- Stage
- Established
Technology & Products
Key Products
Patient-specific titanium cranial implants; 3D printed bioceramic bone substitutes; Craniofacial reconstruction systems
Technological Advantage
CGBio leverages a vertically integrated model combining regenerative medicine expertise with in-house AM production. Their ability to deliver sterilized, patient-specific implants within 5 days is a significant competitive advantage in the time-sensitive trauma surgery market, supported by regulatory clearances for both titanium and bioceramic 3D printed implants.
Differentiation
Value Proposition
Reduces surgical planning and implant lead times to 5 days, improving patient outcomes through high-precision, patient-specific anatomical fit and biocompatible materials.
How They Differentiate
Focuses on a shorter 5-day lead time compared to traditional medical device manufacturers; unique dual-capability in both metal (titanium) and ceramic 3D printing for bone regeneration.
Market & Competition
Target Customers
Hospitals, neurosurgeons, and orthopedic surgeons
Industry Verticals
Medical
Competitors
Stryker; DePuy Synthes; OssDsign
Growth & Milestones
Growth Metrics
Reported $360M export deal for regenerative medicine products; established market presence in South Korea and expanding into China.
Major Milestones
Received Korea's first-ever approval for 3D printed bioceramic cheekbone implants